SIHUAN PHARM (00460) surged over 4% again, rising 4.47% to HK$1.87 as of press time, with trading volume reaching HK$66.52 million. On the news front, XUANZHUBIO is conducting its IPO from October 6 to October 10, planning to offer 67.33 million shares globally, with shares expected to commence trading on the Hong Kong Stock Exchange on October 15. XUANZHUBIO was spun off from SIHUAN PHARM. Additionally, SIHUAN PHARM's subsidiary Meiyan Space has recently obtained the National Medical Products Administration's Class III medical device registration certificate for its self-developed "Sodium Hyaluronate Composite Solution for Injection - Dongyan," marking the official entry of China's first L-carnosine composite solution water-light injection into the capital market spotlight.